Spotlight
Clinical
CME
Partners
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Intravitreal triamcinolone for AMD appears promising, but more studies needed
Fort Lauderdale, FL-Intravitreal triamcinolone appears to inhibit the growth of choroidal neovascularization (CNV) and reduce subretinal fluid in the short term, but it needs further evaluation, ac-cording to Mark Gillies, MB, BS, PhD.
Related Videos
Related Content
